tirofiban has been researched along with Recrudescence in 33 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (15.15) | 18.2507 |
| 2000's | 18 (54.55) | 29.6817 |
| 2010's | 9 (27.27) | 24.3611 |
| 2020's | 1 (3.03) | 2.80 |
| Authors | Studies |
|---|---|
| Cai, J; Cao, J; Ding, C; Qu, M; Shi, Z; Wang, H; Wang, Y; Xia, Y; Yan, Z; Zhang, C; Zhang, X | 1 |
| Che, R; Chen, J; Duan, J; Feng, W; Ji, X; Li, C; Liebeskind, D; Ling, F; Shang, S; Song, H; Wang, Y; Wu, C; Wu, L; Zhang, H; Zhao, W | 1 |
| Akdeniz, E; Demir, K; Guvenc, RC; Guvenc, TS; Guzelburc, O; Kalenderoglu, K; Oz, A; Safak, A; Tekkesin, AI; Velibey, Y; Yildiz, U | 1 |
| Huang, SH; Li, W; Li, XS; Liang, CR; Liu, CC; Wang, H; Wang, YJ; Wu, Y; Xu, ZQ; Zhang, LL; Zhang, M | 1 |
| Baik, SK; Hwang, YH; Kang, DH; Kim, YS; Kim, YW; Park, SP | 1 |
| Akpek, M; Arinc, H; Baktir, AO; Ergin, A; Kaya, MG; Oguzhan, A; Saglam, H; Sahin, O; Sarli, B; Urkmez, S | 1 |
| Hwang, YH; Kang, DH; Kim, YS; Kim, YW; Liebeskind, DS | 1 |
| Borklu, EB; Cinier, G; Eren, M; Hayiroglu, MI; Kaya, A; Keskin, M; Tatlisu, MA; Uzman, O | 1 |
| Braun-Dullaeus, RC; Hass, N; Ibrahim, K; Kolschmann, S; Strasser, RH | 1 |
| De Boer, MJ; Dill, T; Gosselink, AT; Hamm, C; Heestermans, AA; Hoorntje, JC; Koopmans, PC; Ten Berg, JM; Van 't Hof, AW; Van Houwelingen, G; Van Werkum, JW | 1 |
| Bates, ER; Chetcuti, S; Grossman, PM; Gurm, HS; Meier, P; Tamhane, U | 1 |
| Anselmi, M; Bolognese, L; Bressers, M; Bristot, L; Campo, G; Colangelo, S; De Cesare, N; Gambetti, S; Garcia-Garcia, HM; Garg, S; Monti, M; Moreno, R; Parrinello, G; Rodriguez, AE; Sarno, G; Serruys, PW; Valgimigli, M | 1 |
| Bolognese, L; Bramucci, E; Campo, G; Colangelo, S; Corrada, E; De Cesare, N; E Rodriguez, A; Ferrante, G; Ferrari, R; Moreno, R; Nazzaro, MS; Pasquetto, G; Piva, T; Prati, F; Presbitero, P; Sheiban, I; Valgimigli, M; Vassanelli, C | 1 |
| Ambrosini, V; Battaglia, S; Cioppa, A; Lo Muzio, L; Rubino, P; Salemme, L; Sorropago, G; Tesoria, T | 1 |
| Antman, EM; Sabatine, MS | 1 |
| Dambrink, JH; de Boer, MJ; de Vries, ST; Gosselink, AT; Hoorntje, JC; Miedema, K; Suryapranata, H; van 't Hof, AW; Zijlstra, F | 1 |
| Chang, HW; Chen, MC; Chen, SM; Fang, CY; Hsieh, YK; Wu, CJ; Yip, HK | 1 |
| Bigonzi, F; Cohen, M; Danchin, N; Gensini, GF; Gurfinkel, EP; Hecquet, C; Huber, K; Krzeminska-Pakula, M; Maritz, F; Santopinto, J; Timerman, A; Vittori, L; White, HD | 1 |
| Antman, EM; Braunwald, E; Cannon, CP; Demopoulos, LA; DiBattiste, PM; Giugliano, RP; McCabe, CH; Morrow, DA; Murphy, SA; Sabatine, MS; Weintraub, WS | 1 |
| Bolton, ED; Braunstein, JB; Chiles, KA; Faraday, N; Gerstenblith, G; Heldman, AW; Schulman, SP | 1 |
| Chen, SM; Fang, CY; Fu, M; Guo, GB; Hsieh, YK; Wu, CJ; Yip, HK | 1 |
| Tcheng, JE | 2 |
| Moliterno, DJ; Steinhubl, SR | 1 |
| Cohen, DJ; Deckelbaum, LI; Gibson, CM; Goel, M; Harris, KE; King, SB; Piana, RN | 1 |
| Braunwald, E; Cannon, CP; Demopoulos, LA; Gormley, GJ; Robertson, DH; Weintraub, WS | 1 |
| Boccuzzi, SJ; Burnette, J; Cohen, DJ; Cook, JR; Culler, S; Kosinski, AS; Weintraub, WS | 1 |
| Califf, RM; Lincoff, AM; Topol, EJ | 1 |
| Deckelbaum, LI; Dodge, JT; Dotani, I; Gibson, CM; Goel, M; King, SB; Marble, SJ; Murphy, SA | 1 |
| Bigonzi, F; Cohen, M; Danchin, N; Fox, KA; Gensini, GF; Gurfinkel, EP; Huber, K; Le-Louer, V; Maritz, F; Timerman, A; Vittori, L; White, H | 1 |
| Berkowitz, SD | 1 |
| Jang, IK; Januzzi, JL; Sabatine, MS; Snapinn, S; Théroux, P | 1 |
| Becker, RC; Denier, D; Gouveia, W; Kimmelstiel, C; MacIsaac, DA; Miele, R; Phang, R; Rand, W; Rehman, A; Rhofiry, J | 1 |
8 review(s) available for tirofiban and Recrudescence
| Article | Year |
|---|---|
Intravenous tirofiban therapy for patients with capsular warning syndrome.
Topics: Adult; Aged; Aged, 80 and over; Disability Evaluation; Female; Functional Status; Humans; Infusions, Intravenous; Ischemic Attack, Transient; Male; Middle Aged; Platelet Aggregation Inhibitors; Recovery of Function; Recurrence; Retrospective Studies; Syndrome; Time Factors; Tirofiban; Treatment Outcome | 2019 |
A comparison of abciximab and small-molecule glycoprotein IIb/IIIa inhibitors in patients undergoing primary percutaneous coronary intervention: a meta-analysis of contemporary randomized controlled trials.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Eptifibatide; Female; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Recurrence; Risk Assessment; Risk Factors; Thrombosis; Time Factors; Tirofiban; Treatment Outcome; Tyrosine | 2009 |
The thrombolysis in myocardial infarction risk score in unstable angina/non-ST-segment elevation myocardial infarction.
Topics: Acute Disease; Angina, Unstable; Anticoagulants; Drug Therapy, Combination; Heparin; Humans; Logistic Models; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prognosis; Recurrence; Risk Assessment; Thrombolytic Therapy; Tirofiban; Troponin; Tyrosine | 2003 |
Glycoprotein IIb/IIIa receptor inhibitors: putting the EPIC, IMPACT II, RESTORE, and EPILOG trials into perspective.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Atherectomy, Coronary; Constriction, Pathologic; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Recurrence; Stents; Tirofiban; Treatment Outcome; Tyrosine | 1996 |
Glycoprotein IIb/IIIa receptor antagonists for the treatment of unstable angina.
Topics: Abciximab; Acetates; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clinical Trials as Topic; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Myocardial Ischemia; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Recurrence; Tirofiban; Treatment Outcome; Tyrosine | 1997 |
Clinical challenges of platelet glycoprotein IIb/IIIa receptor inhibitor therapy: bleeding, reversal, thrombocytopenia, and retreatment.
Topics: Eptifibatide; Hemorrhage; Humans; Myocardial Ischemia; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Recurrence; Risk Factors; Survival Rate; Thrombocytopenia; Tirofiban; Tyrosine | 2000 |
Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease.
Topics: Abciximab; Acetates; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Combined Modality Therapy; Coronary Disease; Drug Monitoring; Eptifibatide; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Infusions, Intravenous; Myocardial Infarction; Patient Selection; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Practice Guidelines as Topic; Recurrence; Risk Factors; Tirofiban; Treatment Outcome; Tyrosine | 2000 |
Current knowledge of the platelet glycoprotein IIb/IIIa receptor antagonists for the treatment of coronary artery disease.
Topics: Abciximab; Acetates; Angina, Unstable; Angioplasty, Balloon, Coronary; Animals; Antibodies, Monoclonal; Coronary Artery Bypass; Coronary Disease; Drug Approval; Eptifibatide; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Mice; Multicenter Studies as Topic; Myocardial Ischemia; Peptides; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Recombinant Fusion Proteins; Recurrence; Safety; Single-Blind Method; Stents; Survival Analysis; Tirofiban; Treatment Outcome; Tyrosine; United States; United States Food and Drug Administration | 2000 |
13 trial(s) available for tirofiban and Recrudescence
| Article | Year |
|---|---|
Acute Effects of Intracoronary Tirofiban on No-Reflow Phenomena in Patients With ST-Segment Elevated Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.
Topics: Aged; Coronary Circulation; Coronary Thrombosis; Female; Hospital Mortality; Humans; Male; Middle Aged; Myocardial Infarction; No-Reflow Phenomenon; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Recurrence; Risk Factors; Stents; Time Factors; Tirofiban; Treatment Outcome; Turkey; Tyrosine | 2015 |
Marked reduction of early stent thrombosis with pre-hospital initiation of high-dose Tirofiban in ST-segment elevation myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Coronary Thrombosis; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Electrocardiography; Emergency Medical Services; Female; Fibrinolytic Agents; Hemorrhage; Heparin; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Recurrence; Stents; Thrombolytic Therapy; Ticlopidine; Tirofiban; Tyrosine | 2009 |
Sex-specific benefits of sirolimus-eluting stent on long-term outcomes in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: insights from the Multicenter Evaluation of Single High-Dose Bolus Tirofiban
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Arrhythmias, Cardiac; Drug-Eluting Stents; Female; Humans; Immunoglobulin Fab Fragments; Immunosuppressive Agents; Italy; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Recurrence; Sex Factors; Sirolimus; Tirofiban; Tyrosine | 2012 |
A comparison of two invasive strategies in patients with non-ST elevation acute coronary syndromes: results of the Early or Late Intervention in unStable Angina (ELISA) pilot study. 2b/3a upstream therapy and acute coronary syndromes.
Topics: Angina, Unstable; Coronary Angiography; Death, Sudden, Cardiac; Female; Humans; Male; Middle Aged; Myocardial Infarction; Pilot Projects; Platelet Glycoprotein GPIIb-IIIa Complex; Recurrence; Time Factors; Tirofiban; Treatment Outcome; Tyrosine | 2003 |
Impact of tirofiban on angiographic morphologic features of high-burden thrombus formation during direct percutaneous coronary intervention and short-term outcomes.
Topics: Aged; Angioplasty, Balloon, Coronary; Coronary Angiography; Coronary Circulation; Coronary Thrombosis; Female; Fibrinolytic Agents; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Glycoprotein GPIb-IX Complex; Premedication; Recurrence; Stents; Survival Rate; Thrombolytic Therapy; Tirofiban; Treatment Outcome; Tyrosine | 2003 |
The safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and tirofiban versus placebo in the treatment of acute ST-segment elevation myocardial infarction patients ineligible for reperfusion (TETAMI): a randomized trial
Topics: Administration, Oral; Aspirin; Double-Blind Method; Drug Therapy, Combination; Electrocardiography; Enoxaparin; Female; Fibrinolytic Agents; Heparin; Humans; Incidence; Injections, Intravenous; Injections, Subcutaneous; Male; Middle Aged; Myocardial Infarction; Platelet Glycoprotein GPIIb-IIIa Complex; Recurrence; Time Factors; Tirofiban; Tyrosine | 2003 |
Prospective evaluation of the relationship between platelet-leukocyte conjugate formation and recurrent myocardial ischemia in patients with acute coronary syndromes.
Topics: Adenosine Diphosphate; Adrenergic beta-Antagonists; Aged; Angina, Unstable; Arachidonic Acid; Aspirin; Blood Platelets; C-Reactive Protein; Cell Aggregation; Drug Resistance; Eptifibatide; Female; Heparin; Humans; Leukocytes; Male; Middle Aged; Monocytes; Multivariate Analysis; Myocardial Infarction; Myocardial Ischemia; Neutrophils; Patient Selection; Peptides; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prospective Studies; Receptors, Thrombin; Recurrence; ROC Curve; Tirofiban; Treatment Outcome; Troponin I; Tyrosine | 2004 |
Angiographic and clinical outcome in ST-segment elevation myocardial infarction patients receiving an adjunctive double bolus regimen of tirofiban for primary percutaneous coronary intervention.
Topics: Aged; Angiography; Angioplasty, Balloon, Coronary; Female; Hemorrhage; Humans; Male; Middle Aged; Mortality; Myocardial Infarction; Myocardial Revascularization; Recurrence; Tirofiban; Treatment Outcome; Tyrosine | 2006 |
Six-month angiographic and clinical follow-up of patients prospectively randomized to receive either tirofiban or placebo during angioplasty in the RESTORE trial. Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis.
Topics: Adult; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Atherectomy, Coronary; Combined Modality Therapy; Coronary Angiography; Coronary Artery Bypass; Coronary Circulation; Coronary Disease; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prospective Studies; Recurrence; Reoperation; Tirofiban; Treatment Outcome; Tyrosine | 1998 |
Invasive versus conservative strategies in unstable angina and non-Q-wave myocardial infarction following treatment with tirofiban: rationale and study design of the international TACTICS-TIMI 18 Trial. Treat Angina with Aggrastat and determine Cost of Th
Topics: Adolescent; Angina, Unstable; Angioplasty, Balloon, Coronary; Coronary Angiography; Coronary Artery Bypass; Electrocardiography; Female; Follow-Up Studies; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Recurrence; Research Design; Tirofiban; Treatment Outcome; Tyrosine | 1998 |
Economic impact of GPIIB/IIIA blockade after high-risk angioplasty: results from the RESTORE trial. Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Cohort Studies; Combined Modality Therapy; Coronary Disease; Cost-Benefit Analysis; Double-Blind Method; Female; Hospital Mortality; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Recurrence; Retreatment; Risk Factors; Tirofiban; Tyrosine; United States | 1999 |
Global impairment of coronary blood flow in the setting of acute coronary syndromes (a RESTORE substudy). Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis.
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Atherectomy, Coronary; Collateral Circulation; Confidence Intervals; Coronary Circulation; Coronary Disease; Coronary Vessels; Double-Blind Method; Fibrinolytic Agents; Humans; Multivariate Analysis; Myocardial Infarction; Placebos; Platelet Glycoprotein GPIIb-IIIa Complex; Recurrence; Stents; Tirofiban; Treatment Outcome; Tyrosine | 2000 |
The TETAMI trial: the safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and of tirofiban versus placebo in the treatment of acute myocardial infarction for patients not thrombolyzed: methods and design.
Topics: Adult; Aged; Clinical Protocols; Drug Therapy, Combination; Enoxaparin; Female; Fibrinolytic Agents; Heparin; Humans; Injections, Subcutaneous; Male; Middle Aged; Myocardial Infarction; Placebos; Platelet Glycoprotein GPIIb-IIIa Complex; Recurrence; Survival Rate; Tirofiban; Tyrosine | 2000 |
12 other study(ies) available for tirofiban and Recrudescence
| Article | Year |
|---|---|
Efficacy and Safety of Low-Dose Tirofiban for Acute Intracranial Atherosclerotic Stenosis Related Occlusion with Residual Stenosis after Endovascular Treatment.
Topics: Aged; Aged, 80 and over; Brain Ischemia; Disability Evaluation; Endovascular Procedures; Female; Humans; Intracranial Arteriosclerosis; Male; Middle Aged; Plaque, Atherosclerotic; Platelet Aggregation Inhibitors; Recovery of Function; Recurrence; Retrospective Studies; Risk Factors; Stroke; Time Factors; Tirofiban; Treatment Outcome | 2020 |
Low-Dose Tirofiban Improves Functional Outcome in Acute Ischemic Stroke Patients Treated With Endovascular Thrombectomy.
Topics: Aged, 80 and over; Brain Ischemia; Cerebral Hemorrhage; Combined Modality Therapy; Endpoint Determination; Female; Follow-Up Studies; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Recurrence; Registries; Risk Factors; Stroke; Thrombectomy; Tirofiban; Treatment Outcome; Tyrosine | 2017 |
Effects of Bailout Tirofiban on In-Hospital Outcomes and Long-Term Mortality in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Intervention.
Topics: Adult; Aged; Cerebrovascular Disorders; Coronary Thrombosis; Female; Hospital Mortality; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Recurrence; Retrospective Studies; Risk Assessment; Risk Factors; ST Elevation Myocardial Infarction; Time Factors; Tirofiban; Treatment Outcome | 2019 |
Instant reocclusion following mechanical thrombectomy of in situ thromboocclusion and the role of low-dose intra-arterial tirofiban.
Topics: Adult; Aged; Aged, 80 and over; Angiography; Brain; Brain Ischemia; Female; Fibrinolytic Agents; Humans; Male; Middle Aged; Prospective Studies; Recurrence; Stroke; Thrombectomy; Thrombolytic Therapy; Tirofiban; Treatment Outcome; Tyrosine | 2014 |
Impact of Target Arterial Residual Stenosis on Outcome After Endovascular Revascularization.
Topics: Aged; Cerebral Angiography; Combined Modality Therapy; Computed Tomography Angiography; Diagnosis, Differential; Endovascular Procedures; Female; Humans; Infarction, Middle Cerebral Artery; Intracranial Arteriosclerosis; Magnetic Resonance Angiography; Male; Middle Aged; Prevalence; Recurrence; Retrospective Studies; Risk Factors; Smoking; Thrombectomy; Tirofiban; Treatment Outcome; Tyrosine; Vasospasm, Intracranial | 2016 |
The association of the coronary thrombus burden with all-cause mortality and major cardiac events in ST-segment elevation myocardial infarction patients treated with tirofiban.
Topics: Aged; Cause of Death; Coronary Thrombosis; Female; Hemorrhage; Hospital Mortality; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Proportional Hazards Models; Recurrence; Retrospective Studies; Risk Factors; ST Elevation Myocardial Infarction; Time Factors; Tirofiban; Treatment Outcome; Tyrosine | 2016 |
Reversible clopidogrel resistance due to right ventricular myocardial infarction: risk factor of recurrent stent thrombosis?
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Drug Resistance; Drug Therapy, Combination; Drug-Eluting Stents; Electrocardiography; Enoxaparin; Fibrinolytic Agents; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Recurrence; Risk Factors; Ticlopidine; Time Factors; Tirofiban; Treatment Outcome; Tyrosine; Ventricular Dysfunction, Right | 2008 |
Prediction of 1-year clinical outcomes using the SYNTAX score in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a substudy of the STRATEGY (Single High-Dose Bolus Tirofiban and Sirolim
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Cardiovascular Agents; Coronary Angiography; Disease-Free Survival; Drug-Eluting Stents; Female; Humans; Immunoglobulin Fab Fragments; Kaplan-Meier Estimate; Male; Metals; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; Platelet Aggregation Inhibitors; Predictive Value of Tests; Proportional Hazards Models; Randomized Controlled Trials as Topic; Recurrence; Retrospective Studies; Risk Assessment; Risk Factors; ROC Curve; Severity of Illness Index; Sirolimus; Stents; Thrombosis; Time Factors; Tirofiban; Treatment Outcome; Tyrosine | 2011 |
Percutaneous femoral artery angioplasty with stent-in-stent technique and tirofiban administration.
Topics: Angioplasty, Balloon; Female; Femoral Artery; Fibrinolytic Agents; Humans; Middle Aged; Recurrence; Stents; Thrombosis; Tirofiban; Treatment Outcome; Tyrosine | 2002 |
Implications of upstream glycoprotein IIb/IIIa inhibition and coronary artery stenting in the invasive management of unstable angina/non-ST-elevation myocardial infarction: a comparison of the Thrombolysis In Myocardial Infarction (TIMI) IIIB trial and th
Topics: Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Combined Modality Therapy; Comorbidity; Coronary Disease; Female; Hospitalization; Humans; Life Tables; Male; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Recurrence; Retrospective Studies; Risk Factors; Severity of Illness Index; Stents; Survival Analysis; Thrombolytic Therapy; Tirofiban; Treatment Outcome; Tyrosine | 2004 |
A risk score system for predicting adverse outcomes and magnitude of benefit with glycoprotein IIb/IIIa inhibitor therapy in patients with unstable angina pectoris.
Topics: Adult; Age Distribution; Aged; Angina, Unstable; Coronary Angiography; Drug Therapy, Combination; Electrocardiography; Female; Follow-Up Studies; Heparin; Humans; Male; Middle Aged; Myocardial Ischemia; Odds Ratio; Platelet Glycoprotein GPIIb-IIIa Complex; Predictive Value of Tests; Probability; Proportional Hazards Models; Recurrence; Risk Assessment; Risk Factors; Sensitivity and Specificity; Severity of Illness Index; Sex Distribution; Survival Rate; Tirofiban; Treatment Outcome; Tyrosine | 2001 |
Short-term comparative outcomes associated with the use of GP IIb/IIIa antagonists in patients undergoing coronary intervention.
Topics: Abciximab; Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Creatine Kinase; Drug Therapy, Combination; Eptifibatide; Female; Fibrinolytic Agents; Hemorrhage; Heparin; Humans; Immunoglobulin Fab Fragments; Length of Stay; Male; Middle Aged; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prospective Studies; Recurrence; Retrospective Studies; Survival Rate; Tirofiban; Treatment Outcome; Tyrosine | 2001 |